3-Methylglutaconic aciduria
| 3-Methylglutaconic aciduria | |
|---|---|
| File:3-methylglutaconic acid.svg | |
| Synonyms | 3-MGA |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Developmental delay, muscle weakness, ataxia, hearing loss |
| Complications | N/A |
| Onset | Infancy or childhood |
| Duration | Chronic |
| Types | N/A |
| Causes | Genetic mutation |
| Risks | Family history |
| Diagnosis | Urine organic acid test, genetic testing |
| Differential diagnosis | Leigh syndrome, mitochondrial disorders |
| Prevention | N/A |
| Treatment | Supportive care, dietary management |
| Medication | N/A |
| Prognosis | Variable, depending on subtype |
| Frequency | Rare |
| Deaths | Varies by subtype |
3-Methylglutaconic aciduria is a group of rare metabolic disorders characterized by the accumulation of 3-methylglutaconic acid in the urine. These disorders are often associated with defects in the mitochondria, the energy-producing structures within cells.
Classification[edit]
3-Methylglutaconic aciduria is classified into several types based on the underlying genetic cause and clinical presentation:
- Type I: Also known as Barth syndrome, this type is linked to mutations in the TAZ gene and is characterized by cardiomyopathy, neutropenia, and skeletal myopathy.
- Type II: Also known as Costeff syndrome, it is associated with mutations in the OPA3 gene and presents with optic atrophy, movement disorders, and cognitive impairment.
- Type III: This type is less well-defined and includes a variety of symptoms such as ataxia, spasticity, and dystonia.
- Type IV: Also known as MEGDEL syndrome, it is caused by mutations in the SERAC1 gene and is characterized by deafness, encephalopathy, and leukodystrophy.
- Type V: This type is associated with mutations in the DNAJC19 gene and presents with dilated cardiomyopathy, growth retardation, and male genital anomalies.
Pathophysiology[edit]
The accumulation of 3-methylglutaconic acid is due to defects in the mitochondrial respiratory chain or other mitochondrial functions. These defects lead to impaired energy production and increased production of organic acids, including 3-methylglutaconic acid.
Clinical Features[edit]
The clinical features of 3-methylglutaconic aciduria vary depending on the type and severity of the disorder. Common symptoms include:
Diagnosis[edit]
Diagnosis is typically made through the detection of elevated levels of 3-methylglutaconic acid in the urine using gas chromatography-mass spectrometry (GC-MS). Genetic testing can confirm the specific type of 3-methylglutaconic aciduria by identifying mutations in the associated genes.
Management[edit]
Management of 3-methylglutaconic aciduria is primarily supportive and symptomatic. This may include:
- Nutritional support
- Physical therapy
- Cardiac management
- Hearing aids for hearing loss
Prognosis[edit]
The prognosis of 3-methylglutaconic aciduria varies widely depending on the type and severity of the disorder. Some individuals may have a relatively mild course, while others may experience significant disability and reduced life expectancy.
